Molecular Cancer Research

Table of Contents

AACR American Association for Cancer Research

March 2016 • Volume 14 • Number 3

Highlights of This Issue 239

CELL CYCLE AND SENESCENCE

241 Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic Acid: A Potential Role in Cancer Prevention
Rakesh Dachineni, Guoqiang Ai, D. Ramesh Kumar, Satya S. Sadhu, Hemachand Tummala, and G. Jayarama Bhat

CELL DEATH AND SURVIVAL

253 A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity
Veena S. Mysore, Jerzy Szablowski, Peter B. Dervan, and Patrick J. Frost

CHROMATIN, EPIGENETICS, AND RNA REGULATION

267 Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1
Oliver A. Kent, Joshua T. Mendell, and Robert Rottapel

GENOMICS

278 Proteomic Characterization of Head and Neck Cancer Patient–Derived Xenografts
Hua Li, Sarah Wheeler, Yongseok Park, Zhenlin Ju, Sufi M. Thomas, Michele Fichera, Ann M. Egloff, Vivian W. Lui, Umamaheswar Duvvuri, Julie E. Bauman, Gordon B. Mills, and Jennifer R. Grandis

ONCOGENES AND TUMOR SUPPRESSORS

287 Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma
Daniela Pankova, Yulong Chen, Masahiko Terajima, Mark J. Schliekelman, Brandi N. Baird, Monica Fahrenholtz, Li Sun, Bartley J. Gill, Tegy J. Vadakkan, Min P. Kim, Young-Ho Ahn, Jonathon D. Roybal, Xin Liu, Edwin Roger Parra Cuentas, Jaime Rodriguez, Ignacio I. Wistuba, Chad J. Creighton, Don L. Gibbons, John M. Hicks, Mary E. Dickinson, Jennifer L. West, K. Jane Grande-Allen, Samir M. Hanash, Mitsuo Yamauchi, and Jonathan M. Kurie

296 Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF
Jaclyn F. Hechtman, Ahmet Zehir, Rona Yaeger, Lu Wang, Sumit Middha, Tao Zheng, David M. Hyman, David Solit, Maria E. Arcila, Laetitia Borsu, Jinru Shia, Efsevia Vakiani, Leonard Saltz, and Marc Ladanyi

SIGNAL TRANSDUCTION

302 SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide
Shannon P. Fortin Ensign, Alison Roos, Ian T. Mathews, Harshil D. Dhruv, Serdar Tuncali, Jann N. Sarkaria, Marc H. Symons, Joseph C. Loftus, Michael E. Berens, and Nhan L. Tran

Table of Contents

ABOUT THE COVER



In this issue, Kent and colleagues (page 267) identify miR-31 as a RAS effector that enhanced invasion-migration of pancreatic cancer cells via downregulation of the miR-31 target gene *RASA1* and activation of RhoA. The cover image is an examination of the migratory behavior of Panc-1 cells challenged to wound close when expressing a *RASA1*-transgene lacking the 3′-UTR and thus not under regulation by miR-31. From left to right, the individual panels are a snapshot of Panc-1 cells monitored at 0, 15, 30, and 60 hours. Panc-1 transfected with the pCMV empty vector (top row) show a migration front (blue) that moves into and closes the scratch wound (yellow) over the time course. Comparatively, Panc-1 cells expressing pCMV-*RASA1* (bottom row) have a decreased rate of wound closure.

Molecular Cancer Research

14 (3)

Mol Cancer Res 2016;14:239-312.